PFS and Safety With Nivolumab Plus Ipilimumab in Advanced Melanoma

Article

Marc Ernstoff, MD, director of melanoma, Cleveland Clinic, discusses progression-free survival (PFS) and safety in patients with advanced melanoma (MEL) receiving nivolumab (NIVO) combined with ipilimumab (IPI).

Ernstoff describes the 2:1 randomization of this phase II study. He mentions that management of toxicities is still in development, but they immediately stop treatment when autoimmune toxicities occur.

Marc Ernstoff, MD, director of melanoma, Cleveland Clinic, discusses progression-free survival (PFS) and safety in patients with advanced melanoma receiving nivolumab combined with ipilimumab.

Newsletter

Stay up to date on practice-changing data in community practice.

Subscribe Now!
Recent Videos
Related Content
AUA 2025: A Sneak Peek for Community Oncologists/Urologists

AUA 2025: A Sneak Peek for Community Oncologists/Urologists

Jordyn Sava
April 22nd 2025
Article

At AUA 2025, experts will present on novel bladder cancer therapies, advanced renal cell carcinoma comparisons, frailty in prostate cancer, and more.

Read More

Cancer Research Across Continents: Fujiwara’s Path From Japan to the US

Cancer Research Across Continents: Fujiwara’s Path From Japan to the US

Jordyn Sava;Yu Fujiwara, MD
August 1st 2024
Podcast

In this episode of Emerging Experts, Yu Fujiwara, MD, shares his journey from Japan to the United States and his path to becoming a specialist in hematology and oncology.

Listen

FDA Backs Darovasertib Phase 3 Trial Design in Uveal Melanoma

FDA Backs Darovasertib Phase 3 Trial Design in Uveal Melanoma

Jordyn Sava
April 14th 2025
Article

Following a recent Type D meeting with the FDA, a phase 3 clinical trial design for darovasertib in primary uveal melanoma has been announced.

Read More

Advancing Melanoma Treatment: Hamid on Lifileucel's Role

Advancing Melanoma Treatment: Hamid on Lifileucel's Role

Jordyn Sava;Omid Hamid, MD
July 15th 2024
Podcast

In this episode of Targeted Talks, Omid Hamid, MD, discusses data supporting the use of lifileucel for the treatment of advanced melanoma.

Listen

Gene Expression Test Accurately Predicts Low SLN Positivity Risk in Melanoma

Gene Expression Test Accurately Predicts Low SLN Positivity Risk in Melanoma

Jordyn Sava
April 11th 2025
Article

The DecisionDx-Melanoma test accurately identifies low sentinel lymph node risk in melanoma, according to the DECIDE study.

Read More

Safety Committee Backs PH-762 Dose-Escalation in Skin Cancer Trial

Safety Committee Backs PH-762 Dose-Escalation in Skin Cancer Trial

Jordyn Sava
April 9th 2025
Article

A phase 1b trial is evaluating PH-762 for the treatment of cutaneous squamous cell carcinoma, melanoma and Merkel cell carcinoma.

Read More